UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 88

Sortiert nach

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

The Lancet (British edition), 2009-10, Vol.374 (9700), p.1512-1520

2009

Link zum Volltext

Verfügbarkeit prüfen

The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study

Molecules (Basel, Switzerland), 2019-06, Vol.24 (13), p.2367

2019

Link zum Volltext

Verfügbarkeit prüfen

Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life

Acta haematologica, 2021-05, Vol.144 (3), p.322-326

2021

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo-or chemo-immune therapy

Haematologica (Roma), 2008-06, Vol.93 (6), p.951-952

2008

Link zum Volltext

Verfügbarkeit prüfen

CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

Frontiers in oncology, 2021-11, Vol.11, p.730194-730194

2021

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

The lancet oncology, 2008-04, Vol.9 (4), p.352-358

2008

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Blood, 2017-04, Vol.129 (16), p.2328-2330

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Clinical cancer research, 2010-08, Vol.16 (15), p.3998-4004

2010

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders

Expert opinion on pharmacotherapy, 2015-12, Vol.16 (18), p.2715-2718

2015

Link zum Volltext

Verfügbarkeit prüfen

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

The lancet oncology, 2017-08, Vol.18 (8), p.1076-1088

2017

Link zum Volltext

Verfügbarkeit prüfen

High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial

Haematologica (Roma), 2005-06, Vol.90 (6), p.793-801

2005

Link zum Volltext

Verfügbarkeit prüfen

MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

The Lancet. Haematology, 2021-02, Vol.8 (2), p.e110-e121

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood, 2021-11, Vol.138 (Supplement 1), p.2487-2487

2021

Link zum Volltext

Verfügbarkeit prüfen

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Blood, 2018-11, Vol.132 (Supplement 1), p.2902-2902

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(87)
Berichte
(1)

Sprache

Englisch
(88)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Humans
(28)
Female
(19)
Male
(18)
Middle Aged
(18)
Aged
(17)
Hematology
(17)
Adult
(16)
Disease-Free Survival
(14)
Oncology
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Rituximab
(11)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(9)
Treatment Outcome
(9)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(8)
Prognosis
(8)
Adolescent
(7)
Aged, 80 And Over
(7)
Follow-Up Studies
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study

Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo-or chemo-immune therapy

CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

[18F] Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Suchergebnisse filtern